Dosing & Administration

Dosing Guidelines

For adult chronic moderate to severe plaque psoriasis

The recommended starting dose of ENBREL for adult patients is 50 mg given twice weekly (3 or 4 days apart) for 3 months, followed by a reduction to a maintenance dose of 50 mg per week. Starting doses of ENBREL® of 25 mg or 50 mg per week were also shown to be efficacious. The recommended dose should be administered subcutaneously, using the Enbrel® (etanercept) SureClick® autoinjector or the 50-mg/mL single-use prefilled syringe.

Step-down dosing

  1. ENBREL 50 mg twice weekly for the first 3 months
  2. ENBREL 50 mg once weekly for maintenance after 3 months

A 50-mg dose can be given as one subcutaneous (SC) injection using the Enbrel® SureClick® autoinjector or the 50-mg/mL single-use prefilled syringe. 25-mg/0.5-mL prefilled syringes and 25-mg multi-use vials of ENBREL are also available.

A copy of the Instructions for Use can be downloaded here.

For psoriatic arthritis

The recommended dose of ENBREL for adult patients with psoriatic arthritis is 50 mg per week, given as one SC injection using the Enbrel® SureClick® autoinjector or a single-use 50-mg/mL prefilled syringe. 25-mg/0.5 mL single-use prefilled syringes and the 25-mg vials of ENBREL are also available.

A copy of the Instructions for Use can be downloaded here.

Download Prescribing Information and Medication Guide.


 
INDICATIONS

ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone.

ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older.

ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Supportive data

Moderate to Severe Plaque Psoriasis
In medical studies, nearly half of patients saw 75% skin clearance in their moderate to severe plaque psoriasis in 3 months with ENBREL. Overall, 3 out of 4 patients saw 50% skin clearance in 3 months. ENBREL can work fast; many patients saw improvement within 2 months. Your results may vary.

Psoriatic Arthritis
In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients who used it at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.

ENBREL has 10 years of continuous safety data in RA.1 (In the same cohort in a randomized clinical trial and open label extension study)

1. Data on file, Amgen.

Subcutaneous Injection Options

ENBREL provides you
and your patients the
flexibility of multiple
administration options.

View demonstrations arrow

Debra first started to see her symptoms when she was in high school. At its worst, her plaque psoriasis covered more than 90% of her body.

Debra and her doctor decided to give ENBREL a try.

"For me, ENBREL worked within a few months. It made my plaque psoriasis much less noticeable."
Home
Close